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TO THE EDITOR
Alopecia areata (AA) is a common human
hair loss disorder that affects both sexes
and all age groups. Although the precise
etiopathogenesis of AA remains unknown,
immunological and genetic association
studies have implicated both innate and
acquired immunity. Previous genetic
research has identified several susceptibil-
ity factors. These comprise genes that are
assumed to be involved in inflammation
and in the regulation of T cells or other
forms of immune modulation (Petukhova
et al., 2010; John et al., 2011; Jagielska
et al., 2012), genes in the histo-
compatibility leukocyte antigen (HLA)–
encoding region (Entz et al., 2006;
Petukhova et al., 2010), and various
cytokine genes (Petukhova et al., 2010;
Jagielska et al., 2012; Redler et al., 2012).
To characterize the immune-related
nature of AA further, we used the
Immunochip to analyze a large and
clinically well-characterized sample of
767 AA patients and 1,475 controls of
Central-European origin and then fol-
lowed up the most strongly associated
variants in an independent Central-Eur-
opean sample of 1,016 cases and 1,060
controls (Supplementary Materials and
Methods online). The Immunochip is a
unique custom-based Illumina Bead-
Chip array (Illumina, San Diego, CA)
that enables dense mapping of a large
number of susceptibility loci and risk
variants for immune-mediated disease
(Trynka et al., 2011).
Ethical approval was obtained from
the appropriate ethics committees, and
all participants provided written informed
consent prior to blood sampling.
Following stringent quality control of
the discovery Immunochip data (Supple-
mentary Materials and Methods online),
the strongest associations were observed
for variants of the major histocompa-
tibility complex (MHC) class II DQ beta
1 (HLA-DQB1) and class II DQ alpha 2
(HLA-DQA2), with P-values ranging
from 5.591015 to 1.71 10 19.
Our discovery step also provided sup-
port for a large number of additional
regions of interest that did not pass the
threshold of genome-wide significance
but which did reach nominal signifi-
cance (Supplementary Table S3 online).
To follow up the results of the
discovery step, we first performed a
targeted analysis of the HLA-region. This
involved imputation using SNP2HLA
and a stepwise logistic regression
analysis (Supplementary Material and
Methods online). This approach gener-
ated genome-wide/region-wide signifi-
cant results for three independent HLA-
DQB1 variants (rs9275208: Puncorr.¼
1.7110 19, Pcorr.¼2.1 10 14; sin-
gle-nucleotide polymorphism (SNP)
DQB1_32742309_Cx: Puncorr.¼5.02
 108, Pcorr.¼ 4.25 10 4; HLA_
DQB1_0503: Puncorr.¼5.36108,
Pcorr.¼4.35104). In addition,
genome-wide/region-wide significant
results were obtained for variants of
three further HLA-loci (HLA-DQA2,
HLA-C, and HLA-DRB1; Supplemen-
tary Table S1 online). However, these
three association signals were probably
dependent on the detected HLA-DQB1
association signals.
In a subsequent step, the 35 most
strongly associated susceptibility var-
iants outside the HLA region were
followed up in our independent case-
control sample. These variants were
selected by choosing a maximum
of two SNPs from all regions with
nominal significance in the discovery step
(Supplementary Materials and Methods
online). Three of these 35 genotyped
variants (rs4916209, rs11904361, and
rs10798176) were replicated with
nominal significance (Table 1). To
obtain robust evidence for association,
we performed a meta-analysis of the
data from the discovery and follow-up
cohorts. In this analysis, all three repli-
cated variants failed to surpass the
threshold of genome-wide significance
but reached nominal significance as
follows (Table 1): (i) Tumor necrosis
factor (TNF; ligand) superfamily,
member 4 (TNFSF4) variant rs4916209:
Pcomb.¼ 6.8510 07; (ii) Thyroid
adenoma associated (THADA) variantAccepted article preview online 22 October 2014; published online 13 November 2014
Abbreviations: AA, alopecia areata; FASLG, Fas ligand (TNF superfamily, member 6); GWA, genome-wide
association; HLA-DQA2, MHC class II DQ alpha 2; HLA-DQB, MHC class II DQ beta; KIAA0350/
CLEC16A, C-type lectin domain family 16, member A; MHC, major histocompatibility complex; OX40L,
OX40 ligand; THADA, thyroid adenoma associated; TNF, tumor necrosis factor; TNFSF4, TNF (ligand)
superfamily, member 4
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rs11904361: Pcomb.¼ 3.04 1005; and
(iii) Fas ligand (TNF superfamily, member
6; FASLG) variant rs10798176: Pcomb.¼
7.2 10 05 (Table 1). None of the re-
maining 32 genotyped variants were repli-
cated (Supplementary Table S3 online).
Finally, conditional analyses were
performed by fitting the SNP with the
primary association signal of the known
AA susceptibility loci as a covariate into
a logistic regression model (Supple-
mentary Materials and Methods online).
This approach identified a to our knowl-
edge yet unreported susceptibility var-
iant of C-type lectin domain family 16,
member A (KIAA0350/CLEC16A—16-
11135145-A-INSERTION; Supplemen-
tary Table S2 online).
Collectively, we identified HLA-DQB1
as a genome-wide significant AA
susceptibility locus and a to our know-
ledge previously unreported KIAA0350/
CLEC16A variant. Our results suggest
that follow-up studies are warranted for
the three additional loci with nominal
significance––i.e., TNFSF4, THADA, and
FASLG.
Previous research has established that
the HLA region on chromosome 6p21.3
is a key locus in the origin of the
majority of autoimmune-mediated dis-
orders, including AA (Catalog of
Published Genome-Wide Association
Studies: http://www.genome.gov/
gwastudies/; Entz et al., 2006;
Barahmani et al., 2008; Petukhova
et al., 2010). In the present study, fine-
mapping was performed using a publi-
shed imputation and analysis protocol,
which is the most comprehensive HLA-
analysis approach to AA published to
date. In accordance with previous
findings, we obtained both genome-
wide significant results for HLA-DQB1
and support for the predominant role of
the HLA class II region in the association
of the MHC region with AA (Entz et al.,
2006; Barahmani et al., 2008; Petukhova
et al., 2010). Furthermore, we identi-
fied three independent variants of HLA-
DQB1 (Supplementary Table S1 online),
which widens the spectrum of HLA
variants implicated in AA.
As regards TNFSF4, THADA, and
FASLG, all three loci have been asso-
ciated with Crohn’s disease (Franke et al.,
2010), thus pointing to a previously
unknown genetic overlap between these
two autoimmune disorders. Previous
authors have also reported THADA as a
susceptibility locus for thyroid adenomas
(Franke et al., 2010; Patsopoulos et al.,
2011), which is consistent with the
clinical observation of comorbid thyroid
disease and AA (Goh et al., 2006).
FASLG encodes a protein that has a
role in the regulation of cell growth and
apoptosis (Niederkorn, 2006). TNFSF4,
which is also known as OX40 ligand
(OX40L), belongs to the TNF family.
TNFSF4 encodes the cytokine OX40L
(Al-Shamkhani et al., 1997) and acts as
a ligand for OX40, leading to the
assembly of a signaling complex (So
et al., 2011). The OX40–OX40L inter-
action has been implicated in a wide
range of immune-modulating processes
(Croft et al., 2009). Blockade of the
OX40–OX40L complex suppresses the
development of autoimmune and
chronic inflammatory disorders in mice
(Higgins et al., 1999). Inhibition of the
formation of this complex might there-
fore represent a potential treatment
approach for AA patients. However,
further studies are required to prove
this hypothesis.
The identified KIAA0350/CLEC16A
variant (16-11135145-A-INSERTION) is
probably the best tagging SNP for the
causal variant of this known AA suscept-
ibility locus.
In summary, our results provide
support for the hypothesis that AA has
an autoimmune origin and that T-cell
pathways have a crucial role in its
development. Our results also suggest
that inhibition of the OX40–OX40L
interaction has potential as a thera-
peutic approach. Elucidation of AA
pathophysiology and the development
of further therapeutic options would
represent ground-breaking achieve-
ments in research into this common
autoimmune disorder.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank all patients for their participation in the
study. We thank Bernd Po¨tzsch (Institute of Experi-
mental Hematology and Transfusion Medicine,
University of Bonn) for help with collecting DNA
samples from anonymous blood donors. SR was a
recipient of a BONFOR Gerok fellowship from the
Medical Faculty of the University of Bonn. RCB
and MMN are members of the DFG-funded
Excellence Cluster ImmunoSensation. MMN is
the recipient of a grant from the Alfried Krupp
von Bohlen und Halbach-Stiftung. RCB is the
recipient of a Heisenberg Professorship from the
German Research Foundation (DFG).
Silke Redler1, Marina Angisch2,
Stefanie Heilmann1,3, Sabrina Wolf1,
Sandra Barth1,3, Buket F. Basmanav1,
Kathrin A. Giehl4, Sandra Hanneken5,
Sibylle Eigelshoven5,
Elisabeth Mangold1, Roland Kruse6,
Table 1. Meta-analysis of data from the Immunochip analysis and the follow-up analysis from the three replicated
markers
SNP Position1
Gene
symbol Chr
Allele
(A/B)
P Immunochip,
k-adjusted2
Allelic OR
(95% CI)3 P follow-up4
Allelic OR
(95% CI)3
P meta-analysis
k-adjusted5
Allelic OR
(95% CI)3
rs10798176 172675525 FASLG 1 C/T 0.0016 1.34 (1.16, 1.56) 0.0354 1.18 (1.03, 1.34) 7.2 10 5 1.27 (1.17, 1.37)
rs4916209 173133489 TNFSF4 1 A/G 0.0001 1.39 (1.22, 1.60) 0.0048 1.2 (1.06, 1.34) 6.85107 1.32 (1.23, 1.41)
rs11904361 43848664 THADA 2 C/T 0.0015 0.69 (0.58, 0.84) 0.0261 0.76 (0.53, 0.99) 3.04105 0.72 (0.65, 0.79)
Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism.
1In base pairs, NCBI build 37.5.
2P-values from the Central-European patients genotyped using the Immunochip.
3OR calculation based on the minor allele.
4P-values from the follow-up analysis.
5P-values combined from the Immunochip data and the follow-up sample.
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TO THE EDITOR
Junctional epidermolysis bullosa (JEB) is
a group of genodermatoses character-
ized by clefting in the epidermal base-
ment membrane owing to absent or
defective anchoring proteins. If the het-
erotrimer laminin-332 is absent, affected
individuals suffer from widespread blis-
tering and erosions of skin and mucous
membranes with exuberant granulation
tissue and usually die within the first
year of life (Herlitz type of JEB). If
laminin-332 is produced but defective,
life expectancy may be almost normal
despite considerable blistering (non-
Herlitz JEB; Mu¨hle et al., 2005; Fine
et al., 2008). Mutations in the gene
LAMB3 affecting the b3 chain of
laminin-332 most frequently underlie
JEB (Schneider et al., 2007).
So far, treatment of JEB has only been
supportive. Future therapeutic options
may arise from bone marrow stem cells
(Tolar et al., 2009) or from gene therapy,
e.g., by means of autologous epidermal
stem cells modified ex vivo (Mavilio
et al., 2006; Di Nunzio et al., 2008) or
by prenatal gene transfer (Mu¨hle et al.,
2006; Endo et al., 2012). Before clinical
application, such therapeutic approa-
ches have to be evaluated in animals.
Mouse models lacking the a3, b3, or g2
chain of laminin-332 exist (Kuster et al.,
1997; Ryan et al., 1999; Meng et al.,
2003), but affected animals die shortly
after birth. Thus, long-term effects of
therapeutic approaches cannot be eva-
luated in these models (Mu¨hle et al.,
2006). There is one mouse strain with
a hypomorphic mutation of LAMC2
resulting in non-Herlitz JEB in homo-
zygous animals (Bubier et al., 2010);
however, LAMC2 mutations cause
only a minority of human JEB cases
(Schneider et al., 2007). A mouse
model with a defective LAMB3 gene thatAccepted article preview online 28 October 2014; published online 4 December 2014
Abbreviations: cDNA, complementary DNA; JEB, junctional epidermolysis bullosa; PTC, premature
termination codon
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